Heart Transplant vs LVAD: Which Is Better for End-Stage Failure?

Transplant is still the best long-term answer for end-stage heart failure when the patient qualifies. Median survival crosses 12 years in well-selected cases. LVAD data is close for one-year outcomes, above 80 percent on current devices, but the long-term gap remains real. The choice between them isn’t a simple better-or-worse question. It comes down to who can actually get a transplant, how long the wait is, what the right ventricle is doing, and what the clinical team is trying to achieve with this particular patient.

According to Dr. Vishal Khullar, a Cardiac Surgeon in Mumbai, “Transplant takes the failing heart out. LVAD keeps it running with support. Both work for the right patient but they solve different problems and picking the wrong one causes real harm.”

Two paths. Genuinely different clinical situations. Here is how they actually compare.

Eligibility gap: Transplant criteria are strict by design. Age, organ function, psychosocial stability, no active infection or major contraindication. LVAD eligibility is broader so patients who can’t qualify for transplant still have a meaningful route.

Donor shortage: No donor, no transplant. Waiting times in India stretch months to years and some listed patients never receive an organ. LVAD implantation happens as soon as the decision is made. For a patient deteriorating fast on inotropes, that difference is significant.

Device burden: A driveline exits the body for as long as the patient is on LVAD support. With destination therapy that can run years. Exit site infection is the primary cause of LVAD mortality over time. Immunosuppression is a burden too but doesn’t involve hardware through the skin.

Bridge role
These options aren’t mutually exclusive. LVAD keeps deteriorating patients alive and stable on the transplant list. When a donor arrives, the LVAD comes out and the transplant happens. Sequential pathway, not a competing choice.

For what the donor shortage actually looks like in practice, read our blog on donor wait time.

Dr. Vishal Khullar is the Director of Cardiovascular and Thoracic Surgery, Heart and Lung Transplant at Fortis Hospital Mulund and Fortis S.L. Raheja Hospital, Mumbai. Over 30 years in the field. Training at Cleveland Clinic and Mayo Clinic in the USA. More than 300 heart and lung transplants completed alongside a high volume of LVAD implantations and mechanical circulatory support decisions.

His end-stage failure assessments cover both pathways. Patients get a straight answer on which option fits their clinical picture, and why. Call +91 99870 77880 to book your consultation.

1. PMC (NIH) – LVAD as Bridge to Transplantation 
2. NHLBI – Heart Transplant